LENZ Stock Overview
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
LENZ Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.87 |
| 52 Week High | US$24.59 |
| 52 Week Low | US$15.05 |
| Beta | 0 |
| 1 Month Change | -28.93% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -2.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| LENZ | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.3% | 0.1% | 2.2% |
| 1Y | n/a | -1.0% | 22.8% |
Return vs Industry: Insufficient data to determine how LENZ performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how LENZ performed against the US Market.
Price Volatility
| LENZ volatility | |
|---|---|
| LENZ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LENZ's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine LENZ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Eef Schimmelpennink | www.lenz-tx.com |
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
LENZ Therapeutics, Inc. Fundamentals Summary
| LENZ fundamental statistics | |
|---|---|
| Market cap | US$405.22m |
| Earnings (TTM) | -US$69.97m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.8x
P/E RatioIs LENZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LENZ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$69.97m |
| Earnings | -US$69.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LENZ perform over the long term?
See historical performance and comparison